University of Virginia and AstraZeneca: ‘Bench to bedside’ partnership in search of novel cardiometabolic therapies

We are working with the University of Virginia to develop innovative treatments for cardiovascular disease. The partnership supports preclinical to clinical research projects aimed at identifying disease mechanisms and biological targets with potential to become successful and commercially viable treatments in areas of high unmet medical need. Principal investigators from the university are matched with AstraZeneca researchers to accelerate the translation of research into new drugs, by tapping into the strengths of both partners.

Related Articles